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Abstract: The complexity of immune system is tempered by precise regulation to maintain
stabilization when exposed to various conditions. A subtle change in gene expression may
be magnified when drastic changes are brought about in cellular development and function.
Posttranslational modifications (PTMs) timely alter the functional activity of immune system, and
work proceeded in these years has begun to throw light upon it. Posttranslational modifications of
histone tails have been mentioned in a large scale of biological developments and disease progression,
thereby making them a central field to investigate. Conventional assessments of these changes
are centered on the transcription factors and cytokines in T cells regulated by variable histone
codes to achieve chromatin remodeling, as well as involved in many human diseases, especially
autoimmune diseases. We here put forward an essential review of core posttranslational modulations
that regulate T cell function and differentiation in the immune system, with a special emphasis on
histone modifications in different T helper cell subsets as well as in autoimmune diseases.
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1. Introduction
The chromatin remodeling happens not only in the modifications themselves but also
in the downstream events they produce for the protein-binding. This can be achieved when
a histone code exists in the functional interaction among multiple histone modifications [1,2].
Although posttranslational modifications of chromatin remodeling are complicated, the significant
donor is the modification of histone tails. A series of posttranslational modifications that are often
generated on one or more histone tails, being a whole to form “histone codes” [3]. These histone
proteins were once considered as dormant elements, but recent evidence have revealed that histones
are integral and dynamic factors responsible for regulating gene transcription. The fundamental
building block of chromatin structure is the highly conserved histone proteins, H2A, H2B, H3, and
H4 [4–6]. Each of the core histones comprises a common domain known as histone fold, and it is
this unit that permits histone–DNA interactions and for dimerization of histones [7]. A tetramer
generated by the combination of the two H3 histones that conduct the interplay of the pairs of H3/H4
heterodimers. This tetramer is then linked to two H2B/H2A heterodimers with two four-helix bundles
as well as histones H2B and H4, thereby giving the core octamer integrity [8]. These core histone
proteins are often found enriched in lysine and arginine residues that can be altered to respond to
external environments, thus permitting regulation of gene expression by affecting the intersection
between DNA and the other chromatin elements. (Figure 1).
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Figure 1. Histone posttranslational in transcriptionally activated and repressed chromatin. 
The fundamental building block is presented as nucleosomal arrays consisting of nucleosomes 
with specific histones and combinations of different histone marks. Nucleosomes with various 
histone marks may differ from the several posttranslational modifications (such as acetylation, 
methylation, phosphorylation, and ubiquitylation). Certain posttranslational modifications (PTMs) 
of the histones can be linked with either activated or silenced chromatin. Transcription output, to 
some extent, is due to dynamic chromatin marks. Therefore, histone PTMs can be a determinant in 
the transcriptional process. Moreover, the adding or removing certain PTMs inside the gene may 
result in the totally different gene expression. A histone PTM that is generally considered to be 
activating can also be found in repressed genes.  
Histone is encoded by an elaborate collection of diverse posttranslational modifications 
including lysine acetylation, arginine and lysine methylation, phosphorylation, ubiquitination (Ub), 
proline isomerization, ADP ribosylation, arginine citrullination, sumoylation, carbonylation and 
biotinylation that directly or indirectly influence chromatin structure [9,10]. Among these 
modifications, acetylation and methylation are the most widely studied [2,11–15]. Functional 
features of these modifications have been implied in a wide range of cell development and 
differentiation.  
1.1. Acetylation 
Histone acetylation refers to adding an acetyl group from one molecular element to histone, while 
the deacetylation is the opposite procedure in which an acetyl group is removed from a histone [16].  
The process of transferring an acetyl group to lysine residues occurs in histone tail, and has the effect 
to eliminate the positive charge to the neutral on the histones. This action also has the potential to 
weaken the interaction of the nucleosome with the DNA backbone, which is negatively charged with 
phosphate groups. This may result in the transformation of a heterochromatin into the euchromatin 
structure, which is associated with the greater level of gene transcription [17,18].  
Histone acetylation is typically regulated by two major kinds of enzymes, known as “histone 
acetyltransferase” (HAT) and “histone deacetylase” (HDAC) [19]. HAT molecules catalyze the 
transfer of an acetyl group while the deacetylation process is characterized by removing acetyl 
groups by enzyme known as Histone deacetylase (HDAC) [20,21]. Acetylation of terminal lysine 
residues is largely indicative of increased gene expression and usually associated with regions of 
actively transcribed chromatin. Conversely, deacetylation performed by HDAC molecules is 
associated with gene repression and is believed as a gene silencing process [21–24]. In this way, 
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with specific histones and combinations of different histone marks. Nucleosomes with various histone
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phosphorylation, and ubiquitylation). Certain posttranslational modifications (PTMs) of the histones
can be linked with either activated or silenc d chromatin. Trans ription output, to som xtent, is due
to dynamic chromatin marks. Therefore, hi tone PTMs can be a determinant in th transcriptional
process. Moreover, the adding or removing certain PTMs inside the gene may result in the totally
different gene expression. A histone PTM that is generally considered to be activating can also be
found in repressed genes.
Histone is encoded by an elaborate collection of diverse posttranslational modifications including
lysine acetylation, arginine a d lysine me hyl tion, ph phorylation, ubiquitination (Ub), proline
isomerization, ADP ribosylation, arginine citrullination, sumoylatio , carbonylation and biotinylation
that directly or indirectly influence chromatin structure [9,10]. Among these modifications, acetylation
and methylation are the most widely studied [2,11–15]. Functional features of these modifications
have been implied in a wide range of cell development and differentiation.
1.1. Acetylation
Histone ace ylation refers to adding a acetyl group from one molecular element to histone, while
the deacetylation is the opposite procedure in which an acetyl group is removed from a histone [16].
The process of transferring an acetyl group to lysine residues occurs in histone tail, and has the effect
to eliminate the positive charge to the neutral on the histones. This action also has the potential to
weaken the interaction of the nucleosome with the DNA backbone, which is negatively charged with
phosphate groups. This may result in e tr nsformation of a hete o h omatin int the euchromatin
structure, which is associated with the greater level of gene transcription [17,18].
Histone acetylation is typically regulated by two major kinds of enzymes, known as “histone
acetyltransferase” (HAT) and “histone deacetylase” (HDAC) [19]. HAT molecules catalyze the transfer
of an acetyl group while the deacetylation process is characterized by removing acetyl groups by
enzyme known as Histone deacetylase (HDAC) [20,21]. Acetylation of terminal lysine residues
is largely indicative of increased gene expression and usually associated with regions of actively
transcribed chromatin. Conversely, deacetylation performed by HDAC molecules is associated with
gene repression and is believed as a gene silencing process [21–24]. In this way, varieties of histone
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deacetylase inhibitors are now widely used as a means of increasing transcription in a hallmark
of genes.
Several lines of evidence in DNA sequencing technology have accelerated our acknowledgement
of histone PTMs distribution patterns in the whole genome. To the best of our understanding, such
advancements have suggested that among acetylated histones [25], histone H3 lysine 27 acetylation
(H3K27ac) has been frequently delineated as being associated with active enhancer regulatory
elements [26]. Specific histone PTMs, such as dimethylation and trimethylation at histone H3 lysines
9 and 27 (H3K9me2, H3K9me3, H3K27me2 and H3K27me3), are frequently established repressive
chromatin states [27]. A tendency of increasingly rifeness of PTMs is discovered in histone protein as
potential biomarkers, such as global difference in histone acetylation or H3K9 and H3K27 methylation,
which are widely used in monitoring disease.
1.2. Methylation
In contrast to acetylation, histone methylation is a complicated process, which is performed
by two histone-modifying enzymes, histone methyltransferases (HMTs) and histone demethylases
(HDMs). The methylation or demethylation processes are frequently found to occur at specific lysine or
arginine residues on histones H3 and H4 [28]. Methylation activities that attenuate chemical interactions
between histone tails and chromatin would accelerate the gene transcription process [29,30].
Methylation of histone tails may also play significant roles in gene activation or repression, and
this lies dominant on what kinds of amino acids are modified, and the number of the methyl groups
added to specific residues. It was shown that different transcriptional outcomes are determined by
methylation of certain residues on histones that are differentially associated with constitution of the
transcription machinery. For example, the addition of three methyl groups to histone 3 at lysine 9
(H3K9me3) or lysine 27 (H3K27me3) is tightly suggested to be linked to transcriptional repression,
when it is upon regulatory control of certain histones at every residue. Nevertheless, dimethylation
of histone H3 at lysine 9 (H3K9me2) is a signature for gene silencing. The occurrence of H3K4me3
and H3K27me3 on distinct genes is considered to be a specialization for poised expression, which
means that the genes are not expressed at present but once activated by some specific signals, they will
express immediately.
1.3. Ubiquitination
Ubiquitination of histone is another process which is performed by adding ubiquitin peptides to
lysine residues. In higher eukaryotes, the most abundant ubiquitin conjugations are ubiquitinated H2A
and H2B. In chromatin, the ubiquitination of histones is frequently found at histone H2B and has been
considered as participating in transcriptional elongation. This process are also known to contribute to
the founding of other involved active signatures on the tails of histone H3 [31]. Ubiquitinated patterns
of these histones are steady in vivo, and their interaction with nucleosomes is put forward to modify
chromatin structure [32].
Even though the exact biologically functions of histone ubiquitination are remained largely
obscure, identified information of this mechanism has implicated them many possible features which
are strongly related to numerous cellular processes, such as DNA repairing, and cellular differentiation,
and meiosis in higher eukaryotes [33–35]. Despite such an array of covalent modifications,
ubiquitination has also been proposed as a highly dynamic modification which are determined
by the activity of isopeptidases called de-ubiquitin enzyme that release the ubiquitin moiety and by the
availability of free ubiquitin [36]. In spite of that distinct regulatory domains are not identified,
mono-ubiquitylation has been noted as the most widely researched. The two most noteworthy
modifications are H2AK119ub1, which is correlated with gene silencing [37], and H2BK123ub1,
which is mentioned to be associated with transcriptional initiation and elongation [38,39].
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1.4. Phosphorylation
Similar to the above modifications, histone phosphorylation has recently been discovered as
another covalent modification of histones. The covalent modification of histones by phosphorylation
has been suggested to be related to DNA repair, apoptotic signaling, and heat shock-induced
pathways [40,41]. Histone phosphorylation takes place on serines, threonines and tyrosines and
constitutes an essential part of the PTMs on chromatin [42]. Interestingly, phosphorylation of serine 10
of histone H3 has been indicated to be involved in altering chromatin structure and function, as well
as regulating transcriptional activation, condensation of chromosomes during mitosis and meiosis,
and regulation of cell division [41]. The degrees of phosphorylation are determined by kinases and
phosphatases that add or remove the phosphate groups, respectively [43].
2. Posttranslational Modification of Histones in CD4+ T Cells
Histones are modulated by a series of posttranslational modifications, most of which are
considered as a reader at each chromatin region and thereby link posttranslational modifications
to cell destiny. In immune system, differentiation of CD4+ T cells is mediated by numerous modulatory
control to specific cell related cytokine or nuclear transcription factor gene expression. This modulatory
control is partly due to the regulation by histone modification which plays a central role in transcription
action. In CD4+ T cells, it has been well established that conjugation between signaling pathways and
environmental cues helps to maintain the cell identity. Such timely sensing of environmental signals
promotes distinct differentiation processes and activates the required transcriptional landscape that is
under control of histone PTMs.
CD4+ helper T cells have been described as expressing cell-related core transcription factor (TF),
which can be modified with a number of distinct marked cytokines [44,45]. It is widely accepted that
the process when naïve CD4+ T cell differentiated in different subsets is dynamic. This is achieved
by a network of strict regulation of transcriptional activity, thus enables them to achieve lineage
integrity and stability. Following antigenic stimulation, the differentiation process of CD4+ T cells is
performed after a combination with the antigen-MHC complex. Then they quickly proliferate and
differentiate into distinct effector and memory subtypes depending mainly on antigenic stimulation.
Moreover, differentiation towards different subsets of T helper cell is mentioned to play a role in
regulating alternative cell fates. For example, fundamental function of a CD4+ T cell differentiation can
be initiated when exposed to an infectious environment, the differentiated T cell lineages thus acquiring
specific immune functions that are responsible for pathogen clearance. In naïve T cells, the specific
gene locus exhibits a silenced (inactive or poised) pattern with some repressed modifications of key
cytokines and TFs. (Figure 2).
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Histone modifications in Th1 and Th2 cell differentiation have been extensively analyzed at the
Th1 (IFN-γ) and Th2 gene cytokine loci. In Th1 cells, Th1 cytokine gene (IFNg) gains permissive histone
modifications (H3 and H4 acetylation, H3K4me3), whereas Th2 cytokine genes gain repressive histone
modifications. Conversely, in Th2 cells, the Th2 cytokine locus gains active histone modifications while
the IFNg locus gains repressive histone modifications. In Th17, iTregs, Th9 and Tfh cells, such histone
marks are permissive and especially regulated in their active genes. H3/H4 acetylation and H3K4me3
are specifically increased in the IL-17, FOXP3, PU.1 and BCL-6 gene promoter, which permit the
differentiation from Naïve T cell into different effector T cells.
2.1. Histone PTMs in Th1/Th2 Cell Development
The process when CD4+ T helper (Th) cells differentiated into Th1 cell subsets is featured by
the production of Th1 specific cytokine interferon gamma (IFNγ), as well as the expression of the
transcription factor T-bet. T-bet serves as an activator in regulating CD4+ T helper cell differentiation.
However, molecular mechanisms that delineate stimulatory and inhibitory function of T-bet when
regulating specific gene expression remain to be verified. Th2 cells are presented in part by expressing
the major TF GATA-3 and producing Th2 specific cytokines, interleukin (IL)-4, IL-5, and IL-13.
Th1 cytokine gene (IFNγ) and Th2 cytokine gene (IL-4, IL-5, and IL-13) loci are expressed in Th1
and Th2 cells, respectively, undergo structural and chromatin modifications during differentiation.
T-bet and Gata3 are two primary transcriptional factors respectively responsible for the induction of
Th1 and Th2 specific cytokines in the differentiation process towards Th1 and Th2 lineages. However,
recently evidence has suggested that the production of such cytokines will not be altered when lack of
the distinct transcription factors after the T helper lineages matured [46–49].
The Th1/Th2 cytokine gene loci have been researched extensively for gene regulation and
lineage-commitment. Th1 and Th2 cells possess variable immune functions; Th1 cells are suggested
to be associated with cell immunity resisted to intracellular bacteria as well as viral infection,
while Th2 cells participate in humoral immunity and immunity against extracellular pathogens.
Thus, dysfunction of Th1 and Th2 cell may initiate inflammatory cascade, which results in autoimmune
disease and allergy, respectively. As is known to all, a number of multifunctional proteins are under
regulation of PTMs and thus determine the cell fates by direct stimulation to target gene expression.
The complicated process of Th1 and Th2 cell differentiation has been deciphered by histone
PTMs and chromatin remodeling at specific loci [50]. Some differentiated Th1- and Th2-specific loci
(IFNg and TBX21 for Th1 cells, and IL4, IL13 and GATA3 for Th2 cells) have been noted to obtain
active histone marks and lose repressive marks. By chromatin immunoprecipitation, naïve CD4+ T cell
always displays few histone acetylations at the promoter region of IFNγ locus as well as the IL4 and
IL13 gene loci. However, the naïve T cells will obtain a large number of positive histone modification
at the promoter of IFNγ locus or negative histone modifications at the promoter region of the IL4 and
IL13 gene loci respectively, once upon an activation to differentiate into a Th1 subset. Positive histone
modifications, such as acetylation of H4 (H4Ac) and H3K4me3 have been found on IFN-γ locus, while
negative histone modifications, such as histone methylation have been found to silence Th2 cytokine
(IL4 and IL13) gene loci. In turn, these modifications are completely exhibited in a different form
when differentiated towards Th2 cells. IL4 and IL13 gene locus displays histone hyperacetylation
while the IFN-γ locus presents negative histone modifications to silence the IFN-γ cytokine gene
expression [51–54].
Histone acetylation is a positive histone modification which is associated with an active chromatin
structure and is also suggested to be found at the promoters of IFN-γ locus and Th2 cytokine–IL4–IL13
locus in memory T helper 1 (Th1) and Th2 cells, respectively [55,56]. Several lines of evidence have
reported the important role of Trithorax G, which can be activated by acetylation of histone H4
and this gene is a well-characterized chromatin modulator during Th2 cell differentiation [57,58].
STAT family is known as a modifier in the lineage-specific chromatin state. Induction of Trithorax
G with STAT6 to displace PRC components in the Gata3 locus can drive Th2 cell development [57].
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Moreover, STAT4 is essential to upregulate the level of permissive marks-H3K4me3 on specific genes
of T helper 1 cell. While STAT6 lose the repressive marks-H3K27me3 in silenced genes of T helper 2
cells. Chromatin remodeling complexes have also been suggested as donors in maintaining the balance
between permissive and repressive gene expression [59]. For example, H3K4-specific methylase MLL
is essential in the maintenance of the expression and stability of IL4 and IL13 genes in Th2 cell [58].
It has been detected that a histone methylase SUV39H1 is involved in the trimethylation of H3K9
(H3K9me3), which can recruit heterochromatin protein to promote the stabilization of gene repression.
This is interesting since the enzyme has been implied to silence Th1 gene loci expression and thus
promoting the stabilization of Th2 cells [60]. Moreover, Ezh2 directly binds and facilitates appropriate
expression of Tbx21 and Gata3 in the differentiation process of Th1 and Th2 cells, alongside with
high levels of trimethylation at lysine 27 of histone 3 (H3K27me3) [61].In this study, a bridge has been
built between Ezh2 histone PTMs and regulatory transcription of cell specific genes when ultimately
differentiated into specific T cell lineage.
2.2. Histone PTMs in Th17 Cell Development
T helper 17 (Th17) cell is characterized by expressing transcriptional factor retinoic orphan
receptor γt (RORγt, encoded by RORC) as well as producing effector cytokines interleukin-17, IL-21,
and IL-22. Th17 cells participate in host defensive systems against several harmful environmental
factors, such as bacterial infection. The effector cytokines of Th17 cell act as bridges between the
immune system and tissue damage thus playing pivotal role in tissue immunity. It has become
increasingly appreciated that histone modifications, such as acetylation or methylation, are widely
found at many Th17 cell-specific gene loci, including RORC, IL-23r, therefore playing significant roles
in maintaining Th17 cell chromatin state [62]. The Rorc loci is indispensable for Th17 development
and exhibits high levels of H3K27Ac and H3K4me3, which are two active regulations during Th17 cell
differentiation [59], as well proved to be marked at the IL17a and IL17f loci [63].
There are many proteins that can identify histone modifications occurring in the chromatin, and
therefore link the genetic material with transcriptional element. Such elements have been noticed in
many studies. BET (bromodomain and extra terminal) protein is one of them, including a series of
subtypes, BRD2, BRD3, BRD4 and BRDT. The BET protein is known to identify histones acetylation
as well as involved in the differentiation process to Th17 lineage. Among this BET group, BRD2 and
BRD4 are known to be attached to IL17a and IL17f locus precisely, thereby modulating diverse effector
Th17 specific cytokines [64]. On the other hand, inhibiting BET proteins results in a disturbance in the
differentiation towards Th17 lineage. In addition, the inhibition will suppress the activation of a fully
differentiated Th17 cells.
2.3. Histone PTMs in Treg Cell Development
Regulatory γT (Treg) cell is characterized by expressing main transcription factor Foxp3 and
secreting cytokines IL-10 and TGF-β. It is well known that Treg cells are important to maintain immune
homeostasis, and thus decreasing the regional immune response via a network of unclearly identified
mechanisms. Foxp3 is requisite for Treg cell development and maintenance of Treg cell-mediated
immunosuppression, and thus acquire immune homeostasis. Hence, chromatin regulatory mechanisms
are suggested to regulate Foxp3 protein function. Posttranslational modifications (PTMs) of histones
have been implicated to quickly change the gene expression level in many TFs, FOXP3 is among
those TFs that can be modified with different kinds of histone posttranslational modifications, such as
acetylation and methylation [65].
It has not been until recently that we have figured out that the differentiation process towards
Treg cell is featured with histone PTMs in major gene activators, generated by FOXP3 [66].
Histone chromatin modifications develop a relatively permissive pattern in transcription activity,
therefore increasing the combination of a transcription factor to lineage-specifying genes. In Tregs,
permissive histone modifications such as H3K4me3 found at Foxp3 promoter region are indispensable
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for the Treg cell differentiation [67–70]. Another permissive regulation is histone acetylation displayed
on the Foxp3 locus appears to be essential for Treg functionality and development. CBP and p300
are marked as histone acetyltransferases, and these two enzymes have been studied to maintain
the development and function of Treg cells [71]. In Tregs, the absence of p300 is unable to survive
and maintain the suppression function in autoimmune disease [72]. It is noteworthy that microbial
metabolites such as short chain fatty acids maintain the homeostasis of colonic regulatory T-cell
like HDAC inhibitors, resulting in enhanced exhibition of acetylation in the Foxp3 locus [73,74].
Notably, Treg-specific demethylation (TSDR) region is known for the recruitment of numerous
permissive histone modifications. Conversely, the function of Foxp3 in iTreg is regulated by TGF-β
signaling, in which H4 acetylation and NFAT are generated [75,76]. More recently, a study has
found that the lack of a histone/protein deacetylases (HDACs), HDAC5 in CD4+ T cells can hardly
differentiate into Treg cells under proper polarizing conditions. This strongly suggests that aiming at
HDAC5 will limit the suppressive function and de-novo induction of Treg cells [77].
2.4. Histone PTMs in Other Effector T Cells
The description of excess CD4+ T cell subsets has enlarged our knowledge of Th cell differentiation
beyond histone PTMs. Follicular helper CD4 T (Tfh) cells are specialized in germinal centers to help B
cells to generate T cell–dependent B cell responses [78]. T follicular helper cells (Tfh) are known for
helping B cell to produce antibodies and characterized by expressing the master regulator transcription
factor Bcl6, as well as producing IL-21 cytokine [79,80]. Nonetheless, these two Tfh-related cytokine or
TF are not stable as they are also be expressed by other immune cells, IL-21 is suggested to be secreted
by Th17 cells, while Bcl-6 is central to the development of B cells. However, it is regrettable that few
studies have deciphered the histone PTMs of Tfh differentiation. By ChIP-Seq analyses, Lu et al. has
pointed out that Tbx21, Gata3 and Rorc loci display diverse active histone marks, such as H3K4me3,
in Th cells which are similar to T follicular helper cell, but also ex vivo Tfh cells. [81].
Th9 cell is recently described as a new lineage of T-helper cells, which is defined by producing
interleukin-9 (IL-9). Th9 cells might aggravate the immune response by increasing the level of
antibodies. Additionally, it will also increase the number of infiltrated inflammatory cells in the
respiratory tract. The high level of master transcriptional factor PU.1 (encoded by Spi1) has been linked
to the Th9 lineage commitment [82].
A number of permissive or repressive histone modifications are noticed on the promoter region
of PU.1 to switch the chromatin pattern from naïve CD4+ T cell to Th9 subset. Ramming et al. and
his group have done a network of histone regulation patterns s in promoter regions of PU.1 in naive
and differentiated CD4+ T cells. They have noticed a distinct and dynamic histone-modification
alteration in promoter region at PU.1 gene which is associated with different state of T lymphocytes.
Removal of negative histone mark, with a target repressor can increase the expression level of the
Th9 major transcriptional factor PU.1. By contrast, inhibition of active histone acetylation, with the
histone acetyltransferase inhibitor will in turn decrease expression level of PU.1 upon activation [82].
Another study has demonstrated that two transcriptional factors, Smad2 and Smad4, which are the
products in the TGF-β signaling pathway, are necessary for Th9 differentiation. In the absence of
Smad2 or Smad4, T cells may somehow carried out impaired IL-9, which is consistent with negative
chromatin modification histone H3K27me3 on the IL9 locus [83]. The bridge between histone PTMs
and PU.1 in the process of Th9 development needs further research. It is recognized that PU.1 is
regularly deficient in the region where H3 K27 trimethylation –enriched. In addition, functionality of
PU.1 is frequently mentioned as being related to permissive modification H3K4 dimethylation.
3. Histone PTMs and Autoimmune Diseases
More recently, there is considerable evidence shows that histone PTMs are participated in various
biological processes of the immune system, thus influencing the progression and pathogenesis of
autoimmune diseases. Lack of the ability to maintain the stabilization of internal environment in
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autoimmune diseases is closely related to aberrant histone posttranslational modifications. Here we
present an overview of the latest updates of histone PTMs in the regulation of some common
autoimmune diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), multiple
sclerosis (MS), primary biliary cirrhosis (PBC), and type 1 diabetes mellitus (T1D) (Figure 3).
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This schematic re r sentation illustra es the potential histone modifications, which can alter the
cellu ar gene ex ression profile and thus promote disea es pathology. Ch mical structur s of selected
compounds targeting hist ne modifications are also report d. A simplified scheme illustrating the
structure of mammalian chromatin is also presented.
3.1. Systemic Lupus Erythematosus (SLE)
SLE is an autoimmun dise se with multipl organs i volve . It i characterized by production of
autoantibodies targete to a variety of nuclear antigens and deposit in organs and thus causing tissue
damage by inducing infla mation. Although chronic autoimmune condition in SLE affects almost any
organ system, the pathogenesis of SLE needs a further investigation due to the unclear mechanisms.
Posttranslational histone modifications are associated with the pathogenesis of SLE, as evidenced
both in human patients and mouse models. A characteristic of genes are aberrantly combined with
the presence of permissive and repressive histone PTMs in SLE. Even if histone acetylation effects
on genes are not completely understood in SLE. CD4+ T cell profile of SLE patients with active
disease are characterized by global H3 and H4 hypoacetylation in active lupus CD4+ T cells and
disease activity correlates negatively with H3 acetylation as measured by SLEDAI. Furthermore, global
histone H3K9 hypomethylation, but not H3K4, in both active and inactive lupus CD4+ T cells has
been suggested [84]. Chromatin modifier genes under the regulation of histone PTMs have been
observed to be aberrantly expressed in SLE. Such gene as SIRT1, CREBBP, P300, HDAC2, HDAC7,
SUV39H2, and EZH2 have been documented in SLE CD4+ T cells [84]. Similar to CD4+ T cell of
SLE patients, study on MRL/lpr mice has implied on the role of SIRTI as an important histone
acetylation regulator, in which administratio of SIRT1-siRNA into the MRL/lpr mice co tributes
to SIRT1 under-expression, which in turn resulted i the inc a ed levels of global hist ne H3 and
H4 acet lation in CD4+ T cells [85]. Moreover, differential expre sion of transcript level of histone
methyltransferases (HMTs) and histone demethylases (HDMs) has been established in CD4+ T cells of
MRL/lpr mice [86].
Several lines of evidence have performed many dysregulated transcriptional factors that are
involved in SLE pathogenesis by recruiting histone PTMs. It has been shown that autoimmune
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responses in SLE may partly be explained by Regulatory factor X-box 1 (RFX1) downregulation,
which results in histone H3 hyperacetylation at the promoter region of CD11a and CD70 genein CD4+
T cells of patients with systemic lupus erythematosus (SLE). Accordingly, downregulation of RFX1
contributes to the overexpression of CD11a and CD70, thus resulting an in increased autoreactivity
in SLE [87]. Our further study has confirmed this function of RFX1. We have found that RFX1 can
recruit a histone methyltransferase suppressor of variegation 3–9 (Drosophila) homolog 1 (SUV39H1)
to the CD11a and CD70 genes promoter in CD4+ T cells. In this way, RFX1 can alter the level of histone
modification H3K9me3 [88]. E4BP4 is another transcriptional factor studied in our group with altered
histone modifications in SLE. By binding to the promoter region of CD40L, E4BP4 directly regulates
the level of histone acetylation and methylation in the CD40L, thus influencing CD40L expression.
In human, CD4+ T cells from patients with active SLE exhibit global histone PTMs. These PTMs
are significant in regulating expression level of CD70 (TNFSF7) and CD40L gene, which are associated
with autoreactivity of SLE. It is considered that aberrant histone modifications within the TNFSF7
promoter accompanied with other mechanisms lead the way to the development of lupus through
elevating CD70 level in CD4+ T cells. Zhou et al. found that histone H3 acetylation and dimethylated
H3 lysine 4 (H3K4me2) levels were significantly enhanced in TNFSF7 promoter in CD4+ T cells
from patients with lupus, and these histone modifications correlated positively with disease activity.
In addition, the MeCP2 protein levels in the TNFSF7 promoter were decreased in patients with active
lupus [89]. By chromatin immunoprecipitation (ChIP) microarray data, Zhang et al. has identified
significantly increased level of histone H3 lysine 27 trimethylation (H3K27me3) enrichment at the
hematopoietic progenitor kinase 1 (HPK1), a negative regulator of T cell-mediated immune responses,
promoter of SLE CD4+ T cells relative to controls. It seems that high levels of H3K27me3 at the HPK1
promoter may contribute to T cell overactivation and B cell overstimulation in SLE [90].
Despite the SLE related genes, receptors of the innate immune system also deciphered the function
of histone PTMs in SLE T cells. Toll-like receptor 2 is tightly associated with histone modifications.
An ex vivo experiment shows that upon activation, TLR2 in CD4+ T cells will elevate the level of
both H3K4me3 and H4 acetylation in SLE patients. Additionally, the level of H3K9me3 is declined,
in the IL-17A promoter, while the level of H4 acetylation is increased as well as a decreasing level
ofH3K9me3in the IL-17F promoter region. It is more likely to believe that the overexpression of TLR2
accelerates immune reactivity and enhances expression level of IL-17A and IL-17F largely ascribed
to the histone modifications in SLE [91]. Overexpressing of PP2Ac in mouse CD4+ T cells may partly
results in SLE pathogenesis aimed at modulating IL-17 locus by increasing H3 acetylation via the
activation of interferon regulatory factor 4. Therefore, dysregulation of PP2Ac has been known to be
participated in the pathogenesis of SLE, mainly due to the promotion of inflammatory capacity of
T cells [92].
3.2. Systemic Sclerosis (SSc)
SSc is an autoimmune fibrotic disorder featured with, microvascular dysfunction,
and accumulation of the autoantibodies [85]. Although the exact etiology of the SSc still remains
unclear, it is a multifactorial disorder that seems to be caused by complicated genetic mechanisms,
environmental problems, which are crucial factors that may provide more explanations for
pathogenesis of SSc.
Recent studies have found that overall genome H3K27me3 level is decreased in the CD4+ T cells
from SSc patients when compared with normal people. Specific genes like CD40L, CD70, and CD11a
are indicated to be excessive activated in SSc patients due to the demethylation in their promoter,
may also be regulated by the H3K27me3 pattern. This study also indicated an intriguing founding
of JMJD3, which is one of the H3K27 demethylases, have been overexpressed in SSc CD4+ T cells.
Therefore, there is a negative relationship between the mRNA levels of JMJD3 and H3K27me3 level.
Taken together, decreased level of H3K27me3 contributes to the increased expression of JMJD3 in CD4+
T cells from SSc patients [93].
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3.3. Multiple Sclerosis (MS)
MS is a human inflammatory demyelinating disease, characterized with autoimmune response
against myelin proteins and progressive axonal loss by immune system reactivity that contributes to
various stages of either relapsing or progressive neurological degeneration.
The involvement of histone modifications in MS have been less well studied, although alterations
in the major factors responsible for these modifications have been intensely evaluated. β-arrestin 1
(Arrb1) is a utility signaling factor which is essential to T cell survival. Studies have found an obvious
increased expression of Arrb1 in CD4+ T cells from MS patients; Further, mice which lack the Arrb1
gene are presented to be more likely to survive from experimental autoimmune encephalomyelitis,
which is a classical mouse model for multiple sclerosis. Accordingly, the enhanced expression of
Arrb1 will be associated with the multiple sclerosis. It has been observed that overexpression of
oncogene-Bcl2 is mainly due to the Arrb1–dependent modification of histone H4 acetylation at the
Bcl2 promoter in an animal model of MS [94]. These results imply that histone acetylation level affect
Bcl2 gene expression and is related to the pathogenesis of MS.
3.4. Primary Biliary Cirrhosis (PBC)
PBC is a chronic disease of liver, characterized by high titers of antimitochondrial antibodies and
autoreactive T cells, which may cause destruction of the primary bile ducts, and ultimately developed
into cirrhosis and liver failure [95]. Primary biliary cirrhosis is an autoimmune disease that primarily
affects women.
As discussed in multiple sclerosis, overexpression of β-arrestin 1 in CD4+ T, as well as other T
lymphocytes has also been documented in PBC. Studies have showed that elevated expression of
β-arrestin 1 (Arrb1) occurred in T cells from PBC patients. Autoreactive T lymphocytes are frequently
modulated by β-arrestin 1 (Arrb1), this may increase Arrb1 expression of β-arrestin 1, promote T cell
proliferation; augment interferon generation, and decrease the functionalities of nuclear factor κB
and AP-1. Plus, the regulation of Arrb1 in T cells is multifunctional and is also found to be involved
in increasing histone H4 acetylation in CD40L, LIGHT, IL-17 and interferon-γ promoters, while
decreasing histone H4 acetylation in the promoter regions of TRAIL, Apo2, and HDAC7A [96]. In this
study, it has been demonstrated that Arrb1 can alter the gene expression of several disease related
genes. Thus contributing to the pathogenesis of PBC, with variable mechanisms involved, including
histone acetylation.
3.5. Type 1 Diabetes (T1D)
T1D is an autoimmune chronic disease, mediated by T cells. It is characterized by misrecognizing
self-pancreatic cells for foreign agent and consequently damages the pancreas cells [97]. The two major
types of diabetes are type 1 diabetes (T1D), and type 2 diabetes (T2D).
Several lines of studies have mentioned the critical role of histone modifications in the
phathogenesis and development of T1D. In Treg cells of an autoimmune diabetes mouse model,
the major transcription factor of Treg cell, Foxp3 has been suggested to lose the ability to respond
to histone acetyltransferase-Tip60, and the histone deacetylase HDAC7. Additionally, FOXP3 from
those impaired Treg cells of the mouse model is also regulated by other histone PTMs, such as Ikaros
family zinc finger 4, Eos, which lead to decreased level of histone acetylation in Foxp3 promoter and
increased level of K48-linked polyubiquitylation, these together, resulting in a decreasing number of
Treg cells, thus influence the balance of the autoimmune system [98].
Latent autoimmune diabetes in adults (LADA) is a slow onset T1D. It has been identified that
histone modifications displayed alternative gene expression to delineate how external environments
s influence LADA. Liu et al. have shown a series of histone acetylation in CD4+ T cells from LADA
patients. It has been observed a lower level of H3 acetylation in CD4+ T cells from LADA patients
when compared with normal people .and this may help shed light on explaining the mechanisms
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with an epigenetic view in LADA. One interesting observation is that two LADA related clinically
indications, the glycosylated hemoglobin (HbA1c) and GADA titer, are positively correlated with the
H3 acetylation level in LADA CD4+ cells. Moreover, it has also been indicated that a decreased level
of histone acetyltransferases CREBBP, as well as increased level of histone deacetylases HDAC1 and
HDAC7, are observed in LADA patients. [99].
4. Conclusions
Histones make up the major part of protein constituent of chromatin, which are manipulated
with many types of PTMs mostly occur on their tails. These modifications, taken together, comprise a
“histone code” and could be applied to administrate genome or epigenome alterations, thus helping
to establish a genetic or epigenetic crosstalk beyond DNA sequences. There are many histone
PTM-associated molecules, which, accompanied with their related compounds, aim to evaluate specific
functional states of chromatin, thereby regulating diverse chromatin-involved processes. A substantial
number of recent studies demonstrate that these chromatin effector modules are associated with their
unique histone PTMs. Pivotal characteristics in molecular interactions of histone PTMs have been
summarized to shed a light on mechanisms performed in T cell biology and autoimmune diseases.
Alterations of several histone modification patterns may have far-reaching meanings for biological
processes, notably human diseases.
Acknowledgments: This work was supported by the National Natural Science Foundation of China
(No. 81220108017, No. 81430074, No. 81301357 and No. 30972745), the Ph.D. Programs Foundation of Ministry of
Education of China (No. 20120162130003), the Hunan Provincial Natural Science Foundation of China (13JJ4025
and 14JJ1009), the National Key Clinical Specialty Construction Project of National Health and Family Planning
Commission of the People’s Republic of China, and the Research Fund for Postgraduate Innovation Project of
Central South University (2015zzts309).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Suganuma, T.; Workman, J.L. Crosstalk among histone modifications. Cell 2008, 135, 604–607. [CrossRef]
[PubMed]
2. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature 2000, 403, 41–45. [CrossRef]
[PubMed]
3. Jenuwein, T.; Allis, C.D. Translating the histone code. Science 2001, 293, 1074–1080. [CrossRef] [PubMed]
4. Richmond, T.J.; Davey, C.A. The structure of DNA in the nucleosome core. Nature 2003, 423, 145–150.
[CrossRef] [PubMed]
5. Luger, K.; Richmond, T.J. The histone tails of the nucleosome. Curr. Opin. Genet. Dev. 1998, 8, 140–146.
[CrossRef]
6. Kornberg, R.D.; Lorch, Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote
chromosome. Cell 1999, 98, 285–294. [CrossRef]
7. Arents, G.; Moudrianakis, E.N. The histone fold: A ubiquitous architectural motif utilized in DNA
compaction and protein dimerization. Proc. Natl. Acad. Sci. USA 1995, 92, 11170–11174. [CrossRef]
[PubMed]
8. Luger, K.; Mäder, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome
core particle at 2.8 Å resolution. Nature 1997, 389, 251–260. [PubMed]
9. Tan, M.; Luo, H.; Lee, S.; Jin, F.; Yang, J.S.; Montellier, E.; Buchou, T.; Cheng, Z.; Rousseaux, S.; Rajagopal, N.
Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification.
Cell 2011, 146, 1016–1028. [CrossRef] [PubMed]
10. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693–705. [CrossRef] [PubMed]
11. Cheung, P.; Allis, C.D.; Sassone-Corsi, P. Signaling to chromatin through histone modifications. Cell 2000,
103, 263–271. [CrossRef]
12. Wei, Y.; Yu, L.; Bowen, J.; Gorovsky, M.A.; Allis, C.D. Phosphorylation of histone H3 is required for proper
chromosome condensation and segregation. Cell 1999, 97, 99–109. [CrossRef]
Int. J. Mol. Sci. 2016, 17, 1547 12 of 16
13. Baarends, W.M.; Hoogerbrugge, J.W.; Roest, H.P.; Ooms, M.; Vreeburg, J.; Hoeijmakers, J.H.; Grootegoed, J.A.
Histone ubiquitination and chromatin remodeling in mouse spermatogenesis. Dev. Biol. 1999, 207, 322–333.
[CrossRef] [PubMed]
14. El-Osta, A.; Wolffe, A.P. DNA methylation and histone deacetylation in the control of gene expression:
Basic biochemistry to human development and disease. Gene Expr. 2000, 9, 63–75. [CrossRef] [PubMed]
15. Turner, B.M. Histone acetylation and an epigenetic code. Bioessays 2000, 22, 836–845. [CrossRef]
16. Glozak, M.A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene
2005, 363, 15–23. [CrossRef] [PubMed]
17. Shahbazian, M.D.; Grunstein, M. Functions of site-specific histone acetylation and deacetylation.
Annu. Rev. Biochem. 2007, 76, 75–100. [CrossRef] [PubMed]
18. Kristjuhan, A.; Walker, J.; Suka, N.; Grunstein, M.; Roberts, D.; Cairns, B.R.; Svejstrup, J.Q. Transcriptional
inhibition of genes with severe histone h3 hypoacetylation in the coding region. Mol. Cell 2002, 10, 925–933.
[CrossRef]
19. Parthun, M.R. Hat1: The emerging cellular roles of a type B histone acetyltransferase. Oncogene 2007, 26,
5319–5328. [CrossRef] [PubMed]
20. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349–352.
[CrossRef] [PubMed]
21. Kuo, M.H.; Allis, C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998,
20, 615–626. [CrossRef]
22. Gallinari, P.; Di Marco, S.; Jones, P.; Pallaoro, M.; Steinkuhler, C. HDACs, histone deacetylation and gene
transcription: From molecular biology to cancer therapeutics. Cell Res. 2007, 17, 195–211. [CrossRef]
[PubMed]
23. de Ruijter, A.J.; van Gennip, A.H.; Caron, H.N.; Kemp, S.; van Kuilenburg, A.B. Histone deacetylases
(HDACs): Characterization of the classical HDAC family. Biochem. J. 2003, 370, 737–749. [CrossRef]
[PubMed]
24. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998, 12, 599–606.
[CrossRef] [PubMed]
25. Wang, Z.; Zang, C.; Rosenfeld, J.A.; Schones, D.E.; Barski, A.; Cuddapah, S.; Cui, K.; Roh, T.Y.; Peng, W.;
Zhang, M.Q.; et al. Combinatorial patterns of histone acetylations and methylations in the human genome.
Nat. Genet. 2008, 40, 897–903. [CrossRef] [PubMed]
26. Creyghton, M.P.; Cheng, A.W.; Welstead, G.G.; Kooistra, T.; Carey, B.W.; Steine, E.J.; Hanna, J.; Lodato, M.A.;
Frampton, G.M.; Sharp, P.A.; et al. Histone H3K27ac separates active from poised enhancers and predicts
developmental state. Proc. Natl. Acad. Sci. USA 2010, 107, 21931–21936. [CrossRef] [PubMed]
27. Bonasio, R.; Tu, S.; Reinberg, D. Molecular signals of epigenetic states. Science 2010, 330, 612–616. [CrossRef]
[PubMed]
28. Wood, A.; Shilatifard, A. Posttranslational modifications of histones by methylation. Adv. Protein Chem. 2004,
67, 201–222. [PubMed]
29. Greer, J.M.; McCombe, P.A. The role of epigenetic mechanisms and processes in autoimmune disorders.
Biologics 2012, 6, 307–327. [CrossRef] [PubMed]
30. Gupta, S.; Kim, S.Y.; Artis, S.; Molfese, D.L.; Schumacher, A.; Sweatt, J.D.; Paylor, R.E.; Lubin, F.D.
Histone methylation regulates memory formation. J. Neurosci. 2010, 30, 3589–3599. [CrossRef] [PubMed]
31. Weake, V.M.; Workman, J.L. Histone ubiquitination: Triggering gene activity. Mol. Cell 2008, 29, 653–663.
[CrossRef] [PubMed]
32. Widom, J. Structure, dynamics, and function of chromatin in vitro. Annu. Rev. Biophys. Biomol. Struct. 1998,
27, 285–327. [CrossRef] [PubMed]
33. Redman, K.L.; Rechsteiner, M. Extended reading frame of a ubiquitin gene encodes a stable, conserved,
basic protein. J. Biol. Chem. 1988, 263, 4926–4931. [PubMed]
34. Finley, D.; Chau, V. Ubiquitination. Annu. Rev. Cell Biol. 1991, 7, 25–69. [CrossRef] [PubMed]
35. Jennissen, H.P. Ubiquitin and the enigma of intracellular protein degradation. Eur. J. Biochem. 1995, 231,
1–30. [PubMed]
Int. J. Mol. Sci. 2016, 17, 1547 13 of 16
36. Mimnaugh, E.G.; Chen, H.Y.; Davie, J.R.; Celis, J.E.; Neckers, L. Rapid deubiquitination of nucleosomal
histones in human tumor cells caused by proteasome inhibitors and stress response inducers: Effects on
replication, transcription, translation, and the cellular stress response. Biochemistry 1997, 36, 14418–14429.
[CrossRef] [PubMed]
37. Wang, H.; Wang, L.; Erdjument-Bromage, H.; Vidal, M.; Tempst, P.; Jones, R.S.; Zhang, Y. Role of histone
H2A ubiquitination in Polycomb silencing. Nature 2004, 431, 873–878. [CrossRef] [PubMed]
38. Lee, J.-S.; Shukla, A.; Schneider, J.; Swanson, S.K.; Washburn, M.P.; Florens, L.; Bhaumik, S.R.; Shilatifard, A.
Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell 2007,
131, 1084–1096. [CrossRef] [PubMed]
39. Kim, J.; Guermah, M.; McGinty, R.K.; Lee, J.S.; Tang, Z.; Milne, T.A.; Shilatifard, A.; Muir, T.W.; Roeder, R.G.
RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human
cells. Cell 2009, 137, 459–471. [CrossRef] [PubMed]
40. Ballal, N.; Kang, Y.; Olson, M.; Busch, H. Changes in nucleolar proteins and their phosphorylation patterns
during liver regeneration. J. Biol. Chem. 1975, 250, 5921–5925. [PubMed]
41. Berger, S.L. An embarrassment of niches: The many covalent modifications of histones in transcriptional
regulation. Oncogene 2001, 20, 3007–3013. [CrossRef] [PubMed]
42. Xhemalce, B.; Dawson, M.A.; Bannister, A.J. Histone modifications. Rev. Cell Biol. Mol. Med. 2011. [CrossRef]
43. Oki, M.; Aihara, H.; Ito, T. Role of histone phosphorylation in chromatin dynamics and its implications in
diseases. Subcell. Biochem. 2007, 41, 319–336. [PubMed]
44. Wong, W.F.; Kohu, K.; Chiba, T.; Sato, T.; Satake, M. Interplay of transcription factors in T-cell differentiation
and function: The role of Runx. Immunology 2011, 132, 157–164. [CrossRef] [PubMed]
45. Fontenot, J.D.; Gavin, M.A.; Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+
regulatory T cells. Nat. Immunol. 2003, 4, 330–336. [CrossRef] [PubMed]
46. Mullen, A.C.; Hutchins, A.S.; High, F.A.; Lee, H.W.; Sykes, K.J.; Chodosh, L.A.; Reiner, S.L. Hlx is induced by
and genetically interacts with T-bet to promote heritable TH1 gene induction. Nat. Immunol. 2002, 3, 652–658.
[CrossRef] [PubMed]
47. Zhu, J.; Min, B.; Hu-Li, J.; Watson, C.J.; Grinberg, A.; Wang, Q.; Killeen, N.; Urban, J.F., Jr.; Guo, L.; Paul, W.E.
Conditional deletion of Gata3 shows its essential function in TH1-TH2 responses. Nat. Immunol. 2004, 5,
1157–1165. [CrossRef] [PubMed]
48. Pai, S.Y.; Truitt, M.L.; Ho, I.C. GATA-3 deficiency abrogates the development and maintenance of T helper
type 2 cells. Proc. Natl. Acad. Sci. USA 2004, 101, 1993–1998. [CrossRef] [PubMed]
49. Martins, G.A.; Hutchins, A.S.; Reiner, S.L. Transcriptional activators of helper T cell fate are required for
establishment but not maintenance of signature cytokine expression. J. Immunol. 2005, 175, 5981–5895.
[CrossRef] [PubMed]
50. Lee, G.R.; Kim, S.T.; Spilianakis, C.G.; Fields, P.E.; Flavell, R.A. T helper cell differentiation: Regulation by cis
elements and epigenetics. Immunity 2006, 24, 369–379. [CrossRef] [PubMed]
51. Avni, O.; Lee, D.; Macian, F.; Szabo, S.J.; Glimcher, L.H.; Rao, A. TH cell differentiation is accompanied
by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 2002, 3, 643–651. [CrossRef]
[PubMed]
52. Baguet, A.; Bix, M. Chromatin landscape dynamics of the IL4–IL13 locus during T helper 1 and 2 development.
Proc. Natl. Acad. Sci. USA 2004, 101, 11410–11415. [CrossRef] [PubMed]
53. Kondilis-Mangum, H.D.; Wade, P.A. Epigenetics and the adaptive immune response. Mol. Asp. Med. 2013,
34, 813–825. [CrossRef] [PubMed]
54. Koyanagi, M.; Baguet, A.; Martens, J.; Margueron, R.; Jenuwein, T.; Bix, M. EZH2 and histone 3 trimethyl
lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J. Biol. Chem. 2005, 280, 31470–31477.
[CrossRef] [PubMed]
55. Messi, M.; Giacchetto, I.; Nagata, K.; Lanzavecchia, A.; Natoli, G.; Sallusto, F. Memory and flexibility of
cytokine gene expression as separable properties of human TH1 and TH2 lymphocytes. Nat. Immunol. 2003,
4, 78–86. [CrossRef] [PubMed]
56. Yamashita, M.; Shinnakasu, R.; Nigo, Y.; Kimura, M.; Hasegawa, A.; Taniguchi, M.; Nakayama, T.
Interleukin (IL)-4-independent maintenance of histone modification of the IL-4 gene loci in memory Th2
cells. J. Biol. Chem. 2004, 279, 39454–39464. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1547 14 of 16
57. Onodera, A.; Yamashita, M.; Endo, Y.; Kuwahara, M.; Tofukuji, S.; Hosokawa, H.; Kanai, A.; Suzuki, Y.;
Nakayama, T. STAT6-mediated displacement of polycomb by trithorax complex establishes long-term
maintenance of GATA3 expression in T helper type 2 cells. J. Exp. Med. 2010, 207, 2493–2506. [CrossRef]
[PubMed]
58. Yamashita, M.; Hirahara, K.; Shinnakasu, R.; Hosokawa, H.; Norikane, S.; Kimura, M.Y.; Hasegawa, A.;
Nakayama, T. Crucial role of MLL for the maintenance of memory T helper type 2 cell responses. Immunity
2006, 24, 611–622. [CrossRef] [PubMed]
59. Wei, G.; Wei, L.; Zhu, J.; Zang, C.; Hu-Li, J.; Yao, Z.; Cui, K.; Kanno, Y.; Roh, T.Y.; Watford, W.T.; et al.
Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination
of differentiating CD4+ T cells. Immunity 2009, 30, 155–167. [CrossRef] [PubMed]
60. Allan, R.S.; Zueva, E.; Cammas, F.; Schreiber, H.A.; Masson, V.; Belz, G.T.; Roche, D.; Maison, C.; Quivy, J.P.;
Almouzni, G.; et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature
2012, 487, 249–253. [CrossRef] [PubMed]
61. Tumes, D.J.; Onodera, A.; Suzuki, A.; Shinoda, K.; Endo, Y.; Iwamura, C.; Hosokawa, H.; Koseki, H.;
Tokoyoda, K.; Suzuki, Y.; et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T
helper type 1 and type 2 cells. Immunity 2013, 39, 819–832. [CrossRef] [PubMed]
62. Zhu, J.; Davidson, T.S.; Wei, G.; Jankovic, D.; Cui, K.; Schones, D.E.; Guo, L.; Zhao, K.; Shevach, E.M.;
Paul, W.E. Down-regulation of Gfi-1 expression by TGF-β is important for differentiation of Th17 and
CD103I inducible regulatory T cells. J. Exp. Med. 2009, 206, 329–341. [CrossRef] [PubMed]
63. Akimzhanov, A.M.; Yang, X.O.; Dong, C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine
gene locus during inflammatory helper T cell differentiation. J. Biol. Chem. 2007, 282, 5969–5972. [CrossRef]
[PubMed]
64. Mele, D.A.; Salmeron, A.; Ghosh, S.; Huang, H.R.; Bryant, B.M.; Lora, J.M. BET bromodomain inhibition
suppresses TH17-mediated pathology. J. Exp. Med. 2013, 210, 2181–2190. [CrossRef] [PubMed]
65. Van Loosdregt, J.; Coffer, P.J. Post-translational modification networks regulating FOXP3 function.
Trends Immunol. 2014, 35, 368–378. [CrossRef] [PubMed]
66. Samstein, R.M.; Arvey, A.; Josefowicz, S.Z.; Peng, X.; Reynolds, A.; Sandstrom, R.; Neph, S.; Sabo, P.;
Kim, J.M.; Liao, W.; et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage
specification. Cell 2012, 151, 153–166. [CrossRef] [PubMed]
67. Kitagawa, Y.; Ohkura, N.; Sakaguchi, S. Epigenetic control of thymic Treg-cell development. Eur. J. Immunol.
2015, 45, 11–16. [CrossRef] [PubMed]
68. Morikawa, H.; Ohkura, N.; Vandenbon, A.; Itoh, M.; Nagao-Sato, S.; Kawaji, H.; Lassmann, T.; Carninci, P.;
Hayashizaki, Y.; Forrest, A.R.; et al. Differential roles of epigenetic changes and Foxp3 expression in
regulatory T cell-specific transcriptional regulation. Proc. Natl. Acad. Sci. USA 2014, 111, 5289–5294.
[CrossRef] [PubMed]
69. Schreiber, L.; Pietzsch, B.; Floess, S.; Farah, C.; Jansch, L.; Schmitz, I.; Huehn, J. The Treg-specific demethylated
region stabilizes Foxp3 expression independently of NF-κB signaling. PLoS ONE 2014, 9, e88318. [CrossRef]
[PubMed]
70. Waight, J.D.; Takai, S.; Marelli, B.; Qin, G.; Hance, K.W.; Zhang, D.; Tighe, R.; Lan, Y.; Lo, K.M.;
Sabzevari, H.; et al. Cutting Edge: Epigenetic Regulation of Foxp3 Defines a Stable Population of CD4+
Regulatory T Cells in Tumors from Mice and Humans. J. Immunol. 2015, 194, 878–882. [CrossRef] [PubMed]
71. Liu, Y.; Wang, L.; Han, R.; Beier, U.H.; Akimova, T.; Bhatti, T.; Xiao, H.; Cole, P.A.; Brindle, P.K.; Hancock, W.W.
Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell
development and function. Mol. Cell. Biol. 2014, 34, 3993–4007. [CrossRef] [PubMed]
72. Liu, Y.; Wang, L.; Predina, J.; Han, R.; Beier, U.H.; Wang, L.C.; Kapoor, V.; Bhatti, T.R.; Akimova, T.;
Singhal, S.; et al. Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor
immunity. Nat. Med. 2013, 19, 1173–1177. [CrossRef] [PubMed]
73. Smith, P.M.; Howitt, M.R.; Panikov, N.; Michaud, M.; Gallini, C.A.; Bohlooly, Y.M.; Glickman, J.N.;
Garrett, W.S. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
Science 2013, 341, 569–573. [CrossRef] [PubMed]
74. Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veeken, J.; de Roos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.;
Coffer, P.J.; et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell
generation. Nature 2013, 504, 451–455. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1547 15 of 16
75. Tone, Y.; Furuuchi, K.; Kojima, Y.; Tykocinski, M.L.; Greene, M.I.; Tone, M. Smad3 and NFAT cooperate to
induce Foxp3 expression through its enhancer. Nat. Immunol. 2008, 9, 194–202. [CrossRef] [PubMed]
76. Vaeth, M.; Schliesser, U.; Muller, G.; Reissig, S.; Satoh, K.; Tuettenberg, A.; Jonuleit, H.; Waisman, A.;
Muller, M.R.; Serfling, E.; et al. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates
conventional T cells from Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 2012, 109, 16258–16563.
[CrossRef] [PubMed]
77. Xiao, H.; Jiao, J.; Wang, L.; O’Brien, S.; Newick, K.; Wang, L.C.; Falkensammer, E.; Liu, Y.; Han, R.;
Kapoor, V.; et al. HDAC5 controls the functions of Foxp3+ T-regulatory and CD8+ T cells. Int. J. Cancer 2016,
138, 2477–2486. [CrossRef] [PubMed]
78. Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 2011, 29, 621–663. [CrossRef] [PubMed]
79. Choi, Y.S.; Yang, J.A.; Crotty, S. Dynamic regulation of Bcl6 in follicular helper CD4 T (Tfh) cells.
Curr. Opin. Immunol. 2013, 25, 366–372. [CrossRef] [PubMed]
80. Johnston, R.J.; Poholek, A.C.; DiToro, D.; Yusuf, I.; Eto, D.; Barnett, B.; Dent, A.L.; Craft, J.; Crotty, S. Bcl6 and
Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009, 325,
1006–1110. [CrossRef] [PubMed]
81. Lu, K.T.; Kanno, Y.; Cannons, J.L.; Handon, R.; Bible, P.; Elkahloun, A.G.; Anderson, S.M.; Wei, L.; Sun, H.;
O’Shea, J.J.; et al. Functional and epigenetic studies reveal multistep differentiation and plasticity of
in vitro-generated and in vivo-derived follicular T helper cells. Immunity 2011, 35, 622–632. [CrossRef]
[PubMed]
82. Ramming, A.; Druzd, D.; Leipe, J.; Schulze-Koops, H.; Skapenko, A. Maturation-related histone modifications
in the PU.1 promoter regulate Th9-cell development. Blood 2012, 119, 4665–4674. [CrossRef] [PubMed]
83. Wang, A.; Pan, D.; Lee, Y.H.; Martinez, G.J.; Feng, X.H.; Dong, C. Cutting edge: Smad2 and Smad4 regulate
TGF-β-mediated Il9 gene expression via EZH2 displacement. J. Immunol. 2013, 191, 4908–4912. [CrossRef]
[PubMed]
84. Hu, N.; Qiu, X.; Luo, Y.; Yuan, J.; Li, Y.; Lei, W.; Zhang, G.; Zhou, Y.; Su, Y.; Lu, Q. Abnormal histone
modification patterns in lupus CD4+ T cells. J. Rheumatol. 2008, 35, 804–810. [PubMed]
85. Hu, N.; Long, H.; Zhao, M.; Yin, H.; Lu, Q. Aberrant expression pattern of histone acetylation modifiers and
mitigation of lupus by SIRT1-siRNA in MRL/lpr mice. Scand. J. Rheumatol. 2009, 38, 464–471. [CrossRef]
[PubMed]
86. Long, H.; Huang, W.; Yin, H.; Zhao, S.; Zhao, M.; Lu, Q. Abnormal expression pattern of histone demethylases
in CD4+ T cells of MRL/lpr lupus-like mice. Lupus 2009, 18, 1327–1328. [CrossRef] [PubMed]
87. Zhao, M.; Sun, Y.; Gao, F.; Wu, X.; Tang, J.; Yin, H.; Luo, Y.; Richardson, B.; Lu, Q. Epigenetics and SLE:
RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus
CD4+ T cells. J. Autoimmun. 2010, 35, 58–69. [CrossRef] [PubMed]
88. Zhao, M.; Wu, X.; Zhang, Q.; Luo, S.; Liang, G.; Su, Y.; Tan, Y.; Lu, Q. RFX1 regulates CD70 and CD11a
expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res. Ther. 2010,
12. [CrossRef] [PubMed]
89. Zhou, Y.; Qiu, X.; Luo, Y.; Yuan, J.; Li, Y.; Zhong, Q.; Zhao, M.; Lu, Q. Histone modifications and
methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus
2011, 20, 1365–1371. [CrossRef] [PubMed]
90. Zhang, Q.; Liao, J.; Zhao, M.; Liang, G.; Wu, X.; Zhang, P.; Ding, S.; Luo, S.; Lu, Q. Inhibited expression of
hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding
contributes to autoimmunity in systemic lupus erythematosus. J. Autoimmun. 2011, 37, 180–189. [CrossRef]
[PubMed]
91. Liu, Y.; Liao, J.; Zhao, M.; Wu, H.; Yung, S.; Chan, T.M.; Yoshimura, A.; Lu, Q. Increased expression of TLR2
in CD4+ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through
histone modifications. Eur. J. Immunol. 2015, 45, 2683–2693. [CrossRef] [PubMed]
92. Apostolidis, S.A.; Rauen, T.; Hedrich, C.M.; Tsokos, G.C.; Crispin, J.C. Protein phosphatase 2A enables
expression of interleukin 17 (IL-17) through chromatin remodeling. J. Biol. Chem. 2013, 288, 26775–26784.
[CrossRef] [PubMed]
93. Wang, Q.; Xiao, Y.; Shi, Y.; Luo, Y.; Li, Y.; Zhao, M.; Lu, Q.; Xiao, R. Overexpression of JMJD3 may contribute
to demethylation of H3K27me3 in CD4+ T cells from patients with systemic sclerosis. Clin. Immunol. 2015,
161, 396–399. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 1547 16 of 16
94. Shi, Y.; Feng, Y.; Kang, J.; Liu, C.; Li, Z.; Li, D.; Cao, W.; Qiu, J.; Guo, Z.; Bi, E.; et al. Critical regulation of CD4+
T cell survival and autoimmunity by β-arrestin 1. Nat. Immunol. 2007, 8, 817–824. [CrossRef] [PubMed]
95. Kaplan, M.M. Primary biliary cirrhosis. N. Engl. J. Med. 1996, 335, 1570–1580. [CrossRef] [PubMed]
96. Hu, Z.; Huang, Y.; Liu, Y.; Sun, Y.; Zhou, Y.; Gu, M.; Chen, Y.; Xia, R.; Chen, S.; Deng, A.; et al. β-Arrestin 1
modulates functions of autoimmune T cells from primary biliary cirrhosis patients. J. Clin. Immunol. 2011,
31, 346–355. [CrossRef] [PubMed]
97. Xie, Z.; Chang, C.; Zhou, Z. Molecular mechanisms in autoimmune type 1 diabetes: A critical review.
Clin. Rev. Allergy Immunol. 2014, 47, 174–192. [CrossRef] [PubMed]
98. Bettini, M.L.; Pan, F.; Bettini, M.; Finkelstein, D.; Rehg, J.E.; Floess, S.; Bell, B.D.; Ziegler, S.F.; Huehn, J.;
Pardoll, D.M.; et al. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to
regulatory T cell insufficiency. Immunity 2012, 36, 717–730. [CrossRef] [PubMed]
99. Liu, X.Y.; Xu, J.F. Reduced Histone H3 Acetylation in CD4+ T Lymphocytes: Potential Mechanism of Latent
Autoimmune Diabetes in Adults. Dis. Markers 2015, 2015. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
